Mesothelioma - pemetrexed disodium: review decision - December 2010
Review of TA135: pemetrexed disodium for the treatment of mesothelioma
The Institute was proposing that the existing guidance should be transferred to the ‘static guidance’ list.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal and the guidance will become static guidance.
Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
This page was last updated: 13 April 2015